Big Deal in Cancer Diagnostics Worth $21 Billion Completed.. 'Abbott' Opens New Growth Axis

On March 23, Abbott Laboratories (NYSE: ABT) completed its acquisition of Exact Sciences, a leader in early cancer screening and precision oncology diagnostics, bringing it in as a wholly owned subsidiary. With this transaction, Abbott’s cancer-diagnostics portfolio now encompasses Cologuard for colorectal-cancer screening, the Oncotype DX breast-cancer gene test, OncoDetect for cancer-recurrence monitoring and CancerGuard for multi-cancer early detection.

Abbott expects the deal to strengthen its position in the high-growth U.S. cancer-screening and precision-oncology diagnostics market, adding a new growth driver to its existing high-single-digit revenue trajectory. Concurrently, the company filed a legal opinion in support of a $20 billion senior-note offering—structured in eight tranches maturing between 2029 and 2066—and granted approximately 13,255 restricted shares to Senior Vice President Jacob Orville, boosting his equity value to about $5.3 million (roughly ₩7 billion).

Market observers estimate the acquisition price at $105 per share, or about $21 billion in total, funded through a combination of Abbott’s cash reserves and the new bond issuance. Following the closing, Exact Sciences’ common stock was delisted after its final trade on Nasdaq on March 20. Abbott now aims to capture billions of dollars in incremental annual revenue and reinforce its leadership in early cancer detection and precision oncology.

Headquartered in Abbott Park, Illinois, Abbott Laboratories is a global healthcare company operating in more than 150 countries across four core businesses: diagnostics, medical devices, branded generic pharmaceuticals and nutrition products. The addition of Exact Sciences’ cancer-screening and precision-oncology assets to Abbott’s existing blood, molecular and point-of-care diagnostics platform positions the company for significant long-term growth, driven by an aging population and rising cancer incidence worldwide.